Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Keymed Biosciences, Inc. ( (HK:2162) ) is now available.
Keymed Biosciences Inc. announced that all resolutions proposed at its Annual General Meeting held on June 26, 2025, were passed as ordinary resolutions. The resolutions included the adoption of financial statements, re-election of directors, re-appointment of auditors, and granting of mandates to the board for share issuance and repurchase. This successful meeting indicates strong shareholder support and positions the company for continued strategic operations and governance.
The most recent analyst rating on (HK:2162) stock is a Buy with a HK$60.93 price target. To see the full list of analyst forecasts on Keymed Biosciences, Inc. stock, see the HK:2162 Stock Forecast page.
More about Keymed Biosciences, Inc.
Keymed Biosciences Inc. is a company incorporated in the Cayman Islands, operating in the biosciences industry. The company focuses on developing and commercializing innovative medical solutions and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 3,382,674
Technical Sentiment Signal: Buy
Current Market Cap: HK$13.91B
For a thorough assessment of 2162 stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- ‘Time to Get Off This Train,’ Says Top Analyst About Rigetti Computing Stock Ahead of Earnings
- AMD Stock Heads Into Tuesday’s Earnings With Momentum — Here’s What This Top Investor Expects
- ‘The Big Vote Coming’: Daniel Ives Weighs In on Tesla Stock as Shareholders Decide Musk’s $1 Trillion Pay Package